Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  US Nuclear Corp.    UCLE

US NUCLEAR CORP.

(UCLE)
  Report
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

US Nuclear and Grapheton Provide Significant Advances for Parkinson's Disease Therapy

03/17/2020 | 07:31am EST

Los Angeles, CA, March 17, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- The next chapter in US Nuclear’s (OTC: UCLE) brain-machine interface revolution is treating Parkinson’s Disease.  Over 10 million people live with Parkinson’s Disease worldwide.  Parkinson’s Disease is a degenerative, progressive nervous system disorder that affects nerve cells in deep parts of the brain that control movement and memory.  These nerve cells become impaired and/or die, thereby producing less dopamine thus ultimately causing the symptoms of Parkinson’s Disease.  These symptoms include: tremors or shaking in your limbs, slowed movement, rigid muscles, impaired balance, coordination, and eventually, profound memory loss and dementia.  Fortunately, advances in neurostimulation therapy, such as those made by Grapheton, have made it possible to treat this terrible disease. 

The treatment is called ‘Deep Brain Stimulation’ (DBS) and involves the surgical implantation of electrodes in your brain that send electrical signals to the areas responsible for body movement.  The electrodes do not damage healthy brain tissue or destroy nerve cells; instead they produce electrical impulses that regulate the abnormal impulses, including those caused by Parkinson’s. 

A short video made by University Hospitals on treating Parkinson’s Disease using Deep Brain Stimulation can be viewed here: https://www.youtube.com/watch?v=MDTkuCDQU_4

Grapheton has pushed the development of neurostimulation probes even further.  Current implantable neural probes for DBS have electrodes that do not last longer than few years and batteries that will deplete over time, therefore requiring repeat cranial surgeries that are expensive, inconvenient, and risky.  Current systems also only record electrical signals from the brain and provide a limited window into the complex electrical and chemical interactions at the areas of treatment which can cause side effects. 

Grapheton has solved these issues by:

  1. Creating a new carbon-based electrode that doesn’t corrode and can last as long as 40 years or more, thereby greatly reducing the surgery required for maintenance. 
  2. Creating a new self-charging battery that uses the brain’s own salty liquid environment as the power source, negating the need for battery replacement/maintenance. 
  3. Two-way electrical and chemical communication with brain neurons which allows more effective, tailored, and on-demand electrical stimulation, and eliminates most of the current side-effects thus allowing treatment of a wider variety of patients.

Grapheton will provide the neurostimulation probes while US Nuclear provides the ancillary equipment for processing the electrical signals and data. 

Safe Harbor Act
This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Investors may find additional information regarding US Nuclear Corp. at the SEC website at http://www.sec.gov, or the company’s website at www.usnuclearcorp.com

CONTACT:

US Nuclear Corp. (OTCBB: UCLE)

Robert I. Goldstein, President, CEO, and Chairman

Rachel Boulds, Chief Financial Officer

(818) 883 7043

Email: info@usnuclearcorp.com

Primary Logo


© GlobeNewswire 2020
All news about US NUCLEAR CORP.
01/06US NUCLEAR CORP. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/06US NUCLEAR : 2019 Convertible Debenture Now Fully Converted, Closed, and Flat
AQ
2020US Nuclear Corp. Discusses The Progress of Its MIFTEC Contract and Overhuff T..
NE
2020US Nuclear Corp. Announces Third Quarter 2020 Results
GL
2020US NUCLEAR : Management's Discussion and Analysis of Financial Condition and Res..
AQ
2020US NUCLEAR : and Grapheton Brain Implants to Help Immobilized Patients
AQ
2020US Nuclear and Grapheton Brain Implants to Help Immobilized Patients
GL
2020US NUCLEAR : Secures Its Position at Bioelectronics Startup Grapheton
AQ
2020US Nuclear Secures Its Position at Bioelectronics Startup Grapheton
GL
2020US NUCLEAR : Tritium Monitor Market Soars Due to Construction of $20+ Billion IT..
AQ
More news
Financials (USD)
Sales 2019 3,54 M - -
Net income 2019 -3,16 M - -
Net cash 2019 0,10 M - -
P/E ratio 2019 -4,28x
Yield 2019 -
Capitalization 7,41 M 7,41 M -
EV / Sales 2018 2,02x
EV / Sales 2019 3,85x
Nbr of Employees 20
Free-Float 48,4%
Chart US NUCLEAR CORP.
Duration : Period :
US Nuclear Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
NameTitle
Robert I. Goldstein Chairman, President & Chief Executive Officer
Richard Landry COO & Director-Investor Relations
Rachel Boulds Chief Financial Officer & Secretary
Michael G. Hastings Director
Dell Williamson Director
Sector and Competitors